oppn parties Sub-Standard Drugs: India Must Take Strict Action

News Snippets

  • Maratha quota bill likely to be tabled in Maharashtra assembly today
  • Arvind Kejriwal skips ED summons for the 6th time, says the case is in court and will follow court's decision
  • PM Modi says UP has gone from 'red tape' to 'red carpet' in 7 years of 'double engine' government
  • Farm unions reject government offers, to resume Delhi march from today
  • Centre says some Aadhar cards in Bengal 'deactivated' due to technical glitz, will be activated back soon
  • Supreme Court stays LS privilege panel summons to Bengal officials over BJP MP Sukanta Majumdar injury case
  • Supreme Court junks Sandeshkhali petition, says it cannot be compared to Manipur, asks petitioner to approach Calcutta HC
  • Supreme Court gets tough on Chandigarh mayoral elections, asks for ballot papers and video footage, does not order re-election
  • Government starts withdrawing old small tax demands, up to Rs 25000 per entry till FY 2009-10 and up to Rs 10000 per entry from FY 2010-11 to FY 2014-15 with an overall ceiling of Rs 1 lakh per tax payer
  • Stocks remained positive on Monday: Sensex gained 281 points to 72708 and Nifty 81 points to 22122
  • Jasprit Bumrah likely to be rested for 4th Test while K L Rahul may be back
  • FIH Pro League hockey: India beat Spain 8-7 in shootout
  • SP leader Salim Sherwani, miffed at no Muslim candidate given RS ticket, quits party
  • Army going for big (Rs 57000cr) upgrade in combat vehicles to replace T-72 tanks
  • Mamata Banerjee says the BJP is doing nothing to resolve the Sandeshkhali dispute but instead fanning the fires to escalate it
History created in Supreme Court as Chandigarh mayoral poll ballots counted in court, judges declare AAP candidate Kuldeep Kumar winner after taking into account the votes defaced by returning officer Anil Masih
oppn parties
Sub-Standard Drugs: India Must Take Strict Action

By Sunil Garodia
First publised on 2022-12-31 07:54:11

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

The position of India as the pharmacy of the world (for supplying generic medicines at low cost) is in danger after two successive incidents of supply of allegedly sub-standard and/or spurious products. Close on the heels of ruckus raised by the death of more than 66 children in Gambia (which was allegedly flagged by WHO without proper preliminary inquiry) by drinking paediatric cough syrups made in India by Haryana-based Maiden Pharmaceuticals which allegedly deed not meet the prescribed standards (an inquiry by the Indian government exonerated the manufacturer of any wrongdoing) comes the allegation from Uzbekistan that many children have died there after consuming cough syrups made and supplied by Noida-based Marion Biotech Private Limited. Drug regulators in India have asked the firm to stop production pending an investigation.

Even though nothing has been heard further about the Gambia case (although one is sure that the Central government is taking it up in all forums), this new case complicates matter further. In addition, data from Central Drugs Standard Control Organization (CDSCO) shows that out of 1487 samples picked up by regulatory agencies from drug manufacturers' facilities across India, 83 or 6% were found to be sub-standard. Greed, and the desire to make extra profits, leads some dirty fish among drug manufacturers to use sub-standard material or play around with accepted formulas to endanger lives. This cannot be allowed. Manufacturers have to adhere to good manufacturing practises (GMP) and ensure that no sub-standard product leaves their manufacturing facilities.

The Indian Pharmaceuticals Alliance and the Central and state governments have a huge role in ensuring this. There should be mandatory random checks of export consignments (in addition to periodic checks at manufacturing facilities). Drug manufacturers and the government have to all to ensure that India pharmaceuticals products meet accepted world standards and there is no deviation to maintain India's place as the prominent drug supplier in the world. Drug manufacturers found indulging in cutting corners should be punished as per law and their licences should be cancelled even if one wilful deviation is detected and the promoters should be blacklisted and denied licence to manufacture pharmaceutical drugs in future.